ArticleExperimental brain research2026
Rosiglitazone alleviates white matter injury by inhibiting NLRP3/capspase-1 mediated microglial pyroptosis via downregulating KLF4.
Article in Experimental brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
White matter injury (WMI) is a critical pathological feature of various neurological disorders. Microglial pyroptosis, a form of inflammatory cell death mediated by the NLRP3/caspase-1 inflammasome, exacerbates neuroinflammation and contributes to WMI progression. This study investigated the therapeutic potential of rosiglitazone (ROSI), a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, in alleviating WMI by targeting microglial pyroptosis. In vitro, LPS/ATP-stimulated HMC3 cells exhibited elevated pyroptosis markers (NLRP3, caspase-1, GSDMD, ASC) and inflammatory cytokines (IL-1β, IL-18), which were significantly suppressed by ROSI. ROSI also reduced LPS/ATP-induced injury in co-cultured MO3.13 oligodendrocyte precursor cells (OPCs), improving cell viability and reducing apoptosis. In direct-treatment experiments, ROSI did not significantly affect MO3.13 cell viability, supporting an indirect protective effect on OPCs. Mechanistically, ROSI downregulated KLF4, a transcription factor critical for NLRP3 activation, and this effect was confirmed using KLF4-overexpressing HMC3 cells, where ROSI's anti-pyroptotic effects were abolished. Supplementary GW9662 experiments further suggested that the inhibitory effects of ROSI were not obviously reversed by PPAR-γ antagonism. In vivo, ROSI treatment in a rat model of WMI improved cognitive function, attenuated white matter pathology, and suppressed microglial pyroptosis by reducing NLRP3/caspase-1 activation and inflammatory cytokine release. Notably, ROSI downregulated KLF4 in microglia isolated from WMI rats, further supporting its role in inhibiting pyroptosis. Collectively, these findings demonstrated that ROSI alleviated WMI by inhibiting NLRP3/caspase-1-mediated microglial pyroptosis through downregulation of KLF4, highlighting its potential as a therapeutic strategy for WMI.
Indexed as
Identifiers
42801360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.